China Foods Holdings Ltd., operating primarily through its Chinese subsidiary GXXHIC, focuses on traditional Chinese medicine–based health products and personalized consulting via a multi-channel retail model. Despite the rapidly growing Great Health Industry in China, the company has experienced persistent operating losses from 2022 through 2025, alongside liquidity constraints evidenced by a very low current ratio and negative equity. Regulatory complexities in China, particularly around data security and monopoly oversight, add uncertainty to operational stability. Growth initiatives leveraging consumer-driven manufacturing (C2M) and expanding online and offline sales channels offer potential avenues for improvement, but careful monitoring of regulatory adaptation and financial health remains paramount.